364 related articles for article (PubMed ID: 30391079)
41. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.
Wistuba II; Behrens C; Lombardi F; Wagner S; Fujimoto J; Raso MG; Spaggiari L; Galetta D; Riley R; Hughes E; Reid J; Sangale Z; Swisher SG; Kalhor N; Moran CA; Gutin A; Lanchbury JS; Barberis M; Kim ES
Clin Cancer Res; 2013 Nov; 19(22):6261-71. PubMed ID: 24048333
[TBL] [Abstract][Full Text] [Related]
42. Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy.
Tosoian JJ; Almutairi F; Morais CL; Glavaris S; Hicks J; Sundi D; Humphreys E; Han M; De Marzo AM; Ross AE; Tomlins SA; Schaeffer EM; Trock BJ; Lotan TL
Eur Urol; 2017 May; 71(5):697-700. PubMed ID: 27477529
[TBL] [Abstract][Full Text] [Related]
43.
Faisal FA; Murali S; Kaur H; Vidotto T; Guedes LB; Salles DC; Kothari V; Tosoian JJ; Han S; Hovelson DH; Hu K; Spratt DE; Baras AS; Tomlins SA; Schaeffer EM; Lotan TL
Clin Cancer Res; 2020 Jun; 26(11):2595-2602. PubMed ID: 31969336
[TBL] [Abstract][Full Text] [Related]
44. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
[TBL] [Abstract][Full Text] [Related]
45. The ratio of matrix metalloproteinase to E-cadherin expression: a pilot study to assess mRNA and protein expression among African American prostate cancer patients.
Pettaway CA; Song R; Wang X; Sanchez-Ortiz R; Spiess PE; Strom S; Troncoso P
Prostate; 2008 Sep; 68(13):1467-76. PubMed ID: 18618693
[TBL] [Abstract][Full Text] [Related]
46. Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics.
Jalloh M; Myers F; Cowan JE; Carroll PR; Cooperberg MR
Eur Urol; 2015 Mar; 67(3):451-7. PubMed ID: 24746973
[TBL] [Abstract][Full Text] [Related]
47. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
[TBL] [Abstract][Full Text] [Related]
48. A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors.
Ahmad AS; Vasiljević N; Carter P; Berney DM; Møller H; Foster CS; Cuzick J; Lorincz AT
Oncotarget; 2016 Nov; 7(44):71833-71840. PubMed ID: 27708246
[TBL] [Abstract][Full Text] [Related]
49. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer.
Tewari A; Horninger W; Badani KK; Hasan M; Coon S; Crawford ED; Gamito EJ; Wei J; Taub D; Montie J; Porter C; Divine GW; Bartsch G; Menon M
BJU Int; 2005 Jul; 96(1):29-33. PubMed ID: 15963115
[TBL] [Abstract][Full Text] [Related]
50. Self-Identified African Americans and prostate cancer risk: West African genetic ancestry is associated with prostate cancer diagnosis and with higher Gleason sum on biopsy.
Grizzle WE; Kittles RA; Rais-Bahrami S; Shah E; Adams GW; DeGuenther MS; Kolettis PN; Nix JW; Bryant JE; Chinsky R; Kearns JE; Dehimer K; Terrin N; Chang H; Gaston SM
Cancer Med; 2019 Nov; 8(16):6915-6922. PubMed ID: 31568648
[TBL] [Abstract][Full Text] [Related]
51. African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men.
Yamoah K; Deville C; Vapiwala N; Spangler E; Zeigler-Johnson CM; Malkowicz B; Lee DI; Kattan M; Dicker AP; Rebbeck TR
Urol Oncol; 2015 Feb; 33(2):70.e15-22. PubMed ID: 25304288
[TBL] [Abstract][Full Text] [Related]
52. Association Between African American Race and Clinical Outcomes in Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
Deka R; Courtney PT; Parsons JK; Nelson TJ; Nalawade V; Luterstein E; Cherry DR; Simpson DR; Mundt AJ; Murphy JD; D'Amico AV; Kane CJ; Martinez ME; Rose BS
JAMA; 2020 Nov; 324(17):1747-1754. PubMed ID: 33141207
[TBL] [Abstract][Full Text] [Related]
53. Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma.
Eguchi T; Kadota K; Chaft J; Evans B; Kidd J; Tan KS; Dycoco J; Kolquist K; Davis T; Hamilton SA; Yager K; Jones JT; Travis WD; Jones DR; Hartman AR; Adusumilli PS
Oncotarget; 2016 Jun; 7(23):35241-56. PubMed ID: 27153551
[TBL] [Abstract][Full Text] [Related]
54. Computationally Derived Image Signature of Stromal Morphology Is Prognostic of Prostate Cancer Recurrence Following Prostatectomy in African American Patients.
Bhargava HK; Leo P; Elliott R; Janowczyk A; Whitney J; Gupta S; Fu P; Yamoah K; Khani F; Robinson BD; Rebbeck TR; Feldman M; Lal P; Madabhushi A
Clin Cancer Res; 2020 Apr; 26(8):1915-1923. PubMed ID: 32139401
[TBL] [Abstract][Full Text] [Related]
55. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
56. A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer.
Rade M; Kreuz M; Borkowetz A; Sommer U; Blumert C; Füssel S; Bertram C; Löffler D; Otto DJ; Wöller LA; Schimmelpfennig C; Köhl U; Gottschling AC; Hönscheid P; Baretton GB; Wirth M; Thomas C; Horn F; Reiche K
Mol Med; 2024 Feb; 30(1):19. PubMed ID: 38302875
[TBL] [Abstract][Full Text] [Related]
57. Genetic ancestry and prostate cancer susceptibility SNPs in Puerto Rican and African American men.
Irizarry-Ramírez M; Kittles RA; Wang X; Salgado-Montilla J; Nogueras-González GM; Sánchez-Ortiz R; Guerrios L; Rivera K; Shah E; Prokhorova I; Roberson P; Troncoso P; Pettaway CA
Prostate; 2017 Jul; 77(10):1118-1127. PubMed ID: 28543179
[TBL] [Abstract][Full Text] [Related]
58. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery.
Van den Broeck T; Moris L; Gevaert T; Tosco L; Smeets E; Fishbane N; Liu Y; Helsen C; Margrave J; Buerki C; Davicioni E; Van Poppel H; Everaerts W; Weinmann S; Den R; Davis J; Schaeffer E; Karnes RJ; Claessens F; Joniau S
Eur Urol Oncol; 2019 Sep; 2(5):589-596. PubMed ID: 31411980
[TBL] [Abstract][Full Text] [Related]
59. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
[TBL] [Abstract][Full Text] [Related]
60. Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy.
Tward JD; Schlomm T; Bardot S; Canter DJ; Scroggins T; Freedland SJ; Lenz L; Flake DD; Cohen T; Brawer MK; Stone S; Bishoff J
Clin Genitourin Cancer; 2021 Aug; 19(4):296-304.e3. PubMed ID: 33608228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
